CA
NZ
UK
AU
IND
US
Amneal Pharmaceuticals (NASDAQ:AMRX) shares are climbing sharply today after the company received FDA approval for a generic injectable treatment and began selling it immediately, supported byManufacturingcapacity the company already had in place. Amneal is a diversified pharmaceutical company built around complex generic drugs, specialty …
GRAIL (NASDAQ:GRAL) is one of the biggest gainers in the market today after regulatory staff released briefing documents ahead of an advisory committee meeting for the company's blood-based multi-cancer detection test. The absence of significant concerns in materials like these matters a great deal, …
Moderna (NASDAQ:MRNA) shares are rallying sharply today and closing in on a 52-week high after the company announced that data from its personalized cancer therapy program will be presented at a major European oncology conference next month. The Phase 3 melanoma results in particular …
Mohawk Industries (NYSE:MHK) shares are falling sharply today,Gappingdown at the open and slipping well below key technical support levels following heavy insider selling from the company's chief executive. Mohawk Industries is the world's largest flooring company, manufacturing, sourcing, distributing, andMarketinga broad range of residential …
Accendra Health (NYSE:ACH) connects the NYSE Composite to one of healthcare's clearer structural shifts: the move of medical care out of hospitals and clinics and into patients' own homes. This shift is driven by a combination of cost pressure, patient preference, and advances in …
Demand for mental healthcare could shape Acadia Healthcare's (NASDAQ:ACHC) story because the company operates behavioral-health and psychiatric treatment facilities at a time when demand for such care has been rising steadily across the United States, driven by greater awareness, reduced stigma, and a persistent …
Cell-therapy research could shape Adicet Bio's (NASDAQ:ACET) story because a novel form of cell therapy is essentially the whole company. Adicet is a clinical-stage biotechnology firm developing allogeneic gamma-delta CAR T-cell therapies, engineering a particular type of immune cell to attack disease, and aiming …
Neuroscience treatments shape ACADIA Pharmaceuticals' (NASDAQ:ACAD) story because the company has moved past the milestone that defines most biotechs, its first drug approval, and now faces the different and in some ways harder task of building a durable commercialBusinesswhile continuing to advance new candidates. …
ABVC BioPharma (NASDAQ:ABVC) is a nano-cap drug developer spreading limited resources across several early- and mid-stage programs, betting that at least one can advance far enough to attract a meaningful licensing deal with a larger pharmaceutical partner. That licensing-focused model is a deliberate response …
Hepatitis B research matters for Arbutus Biopharma (NASDAQ:ABUS) because the company has built its pipeline around one of the largest unmet needs in infectious disease: chronic hepatitis B affects hundreds of millions of people worldwide, yet existing treatments largely suppress rather than cure the …
Please wait processing your request...